Glioblastoma — clinical trials in United Kingdom
18 open options
- TRIALPHASE1 / PHASE2RECRUITING
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
TGX-007 · Valaciclovir — 2 sites
- TRIALNARECRUITING
Preoperative Preradiotherapy TTFields
TTFields — 1 site
- TRIALNANOT_YET_RECRUITING
Establishing Radiolabelled PSMA as a Target for Glioma Treatment
PET-MRI · Brain tumour biopsy — 1 site
- TRIALPHASE2RECRUITING
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Nabiximols · Temozolomide · Nabiximols-matched placebo — 22 sites
- TRIALNAENROLLING_BY_INVITATION
Triggered Imaging in Glioblastoma Based on Clinical Outcome Evaluation Compared to Routine: a Feasibility Study
triggered imaging — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Avutometinib · Defactinib · Temozolomide — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
5G-PEARL: Paxalisib in Malignant Brain Tumours
Paxalisib · Temozolomide capsule — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Human ADME Study of [14C]-AZD1390
AZD1390 — 2 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Oral repotrectinib (TPX-0005) — 68 sites
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALNANOT_YET_RECRUITING
Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas
surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines — 1 site
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALPHASE1RECRUITING
Anti-GD2 ADC M3554 in Advanced Solid Tumors
M3554 — 11 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 60 sites
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Plixorafenib — 70 sites
- TRIALPHASE1RECRUITING
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
Ipilimumab (3 mg/kg) — 1 site
- TRIALPHASE2RECRUITING
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ribociclib · Everolimus · Temozolomide (TMZ) — 20 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.